Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02186600 · ClinicalTrials.gov registry record · Phase 3
Heartland Osteoporosis Prevention Study
A Phase 3 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
NCT02186600: Completed Phase 3 study, sponsored by University of Nebraska.
NCT02186600 is a Phase 3 study that has completed, run by University of Nebraska. The registered enrollment target is 276 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02186600, a Phase 3 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the best way to prevent bone loss in the first years after menopause. The HOPS study will compare bone loss at 12 months in women: 1) who take calcium and vitamin D only; 2) who take calcium and vitamin D plus the medication "risedronate"; or 3) who take calcium and vitamin D plus participate in bone-loading exercises. Our central hypothesis is that improvements in bone health will be greater in women randomized to bone-loading exercises with calcium and vitamin D compared to women who take calcium and vitamin D only or women who take calcium and vitamin D plus risedronate.
Primary Outcome
Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group. BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT).
Interventions
- DRUG Risedronate
- DRUG Vitamin D3
- DRUG Calcium Carbonate
- BEHAVIORAL Bone-loading exercises
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2015-02-01 |
| Est. Completion | 2019-06-01 |
| Phase | Phase 3 |
What the finished NCT02186600 record still lists
NCT02186600 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 4 interventions - of which Risedronate is the first listed.
NCT02186600 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02186600 about?
NCT02186600 is a clinical study titled "Heartland Osteoporosis Prevention Study". The purpose of this study is to identify the best way to prevent bone loss in the first years after menopause. The HOPS study will compare bone loss at 12 months in women: 1) who take calcium and vitamin D only; 2) who take calcium and vitamin D plus the medication "risedronate"; or 3) who take calc...
What is the current status of trial NCT02186600?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2015-02-01. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT02186600?
The interventions under investigation include: Risedronate (DRUG), Vitamin D3 (DRUG), Calcium Carbonate (DRUG), Bone-loading exercises (BEHAVIORAL).
Who is sponsoring clinical trial NCT02186600?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02186600's enrollment target sits among peer trials
276 1202nd of 2000 higher than 795 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI